Company

PURMX Therapeutics, Inc.

PURMX Therapeutics develops microRNA-based nucleic acid drugs for malignant thoracic tumors.

About

Founded in 2021 and based in Hiroshima, Japan, PURMX Therapeutics develops nucleic acid drugs containing microRNA to treat malignant thoracic tumors. Its pipeline includes MIRX002, a medicine for malignant pleural mesothelioma. In May 2022, the company raised JPY 850 million in Series A funding from Hiroshima Venture Capital, Mitsubishi UFJ Capital, Osaka University Venture Capital, QB Capital, and University of Tokyo Edge Capital Partners.

3Funding rounds

7Investors

Sign in to see more

Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.

Sign in